Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers developed a promising transdermal agent using Triton X-100-modified polyethyleneimine that successfully delivered genetic material to hair follicle cells in mice, potentially alleviating hair loss due to androgenetic alopecia by promoting cell proliferation and inhibiting apoptosis.

In this study, a novel liposomal peptide formulation significantly enhanced hair growth in mice compared to minoxidil, but results on human tissue penetration were inconclusive, suggesting further research is needed for translation to human use.

This case report details a 28-year-old male with early-stage androgenetic alopecia who experienced significant hair density and thickness improvements following a three-month platelet-rich plasma therapy regimen, supporting its potential efficacy in similar cases.

This study discusses a hypothesis that combining intermittent androgen ablation therapy with finasteride may enhance prostate cancer treatment, though new results from this approach are not yet available.

In this study, PRP therapy did not show significant effectiveness in treating androgenetic alopecia in patients over a 6-month period, with 45% of participants reporting no improvement in hair growth, although adverse effects were minimal and non-serious.

CGF-PF may improve hair loss treatment by targeting hair follicle stem cells more effectively.

This study found that combining hair transplantation with platelet-rich plasma treatment significantly improved hair regeneration, reduced hair loss, and minimized skin lesion areas in patients with androgenic alopecia compared to hair transplantation alone, suggesting enhanced treatment efficacy.

This review discusses the application of PRP therapy in pediatric settings and highlights the current lack of sufficient data for its widespread clinical use.

In this study, PRPF treatment was more effective than PRP alone in improving hair count and hair quality in androgenetic alopecia patients, with PRPF showing significant improvements in various hair growth parameters and having no statistical differences observed in the placebo group.

This study found that valproic acid-loaded microemulsion formulations enhanced skin penetration pathways in guinea pigs compared to an aqueous solution, with composition elements like oil content and surfactant ratios significantly affecting drug delivery performance.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This literature review indicates that combining PRP with minoxidil therapy may improve hair growth and patient satisfaction in androgenetic alopecia compared to monotherapies, though study limitations exist.

The study concluded that the Exprecell™ device for preparing anticoagulant-free f-PRF increases volume yield and simplifies the process while maintaining biological activity comparable to conventional methods, suggesting potential clinical utility.

This study found that goat placenta extract, when combined with PEGylated liposomes and microspicule gel, significantly promoted hair regrowth in patients experiencing hair loss due to chemotherapy by enhancing hair cell proliferation without causing skin irritation over a 12-week application period.

This study found that the anticonvulsant effects of progesterone against PTZ-induced seizures in mice require conversion to allopregnanolone, as shown by the reversal of these effects with a 5alpha-reductase inhibitor.

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

This article discusses the popularity and mechanisms of Platelet Rich Plasma therapy for skin rejuvenation and hair loss, but it reports no new clinical results.

This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.

Finasteride may be cost-effective for preventing prostate cancer in high-risk groups.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

This study found that the efficacy of platelet-rich plasma in treating androgenetic alopecia is higher with increased frequency of sessions, chemically-activated PRP, double centrifugation, and whole-head application, among younger and female patients.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

In this study, the researchers developed a novasome vesicle carrying bovine placenta extract, which demonstrated superior hair growth effects in rats compared to traditional minoxidil and PE-loaded liposomes, and showed good stability and physical characteristics over 90 days at 4°C.

This study found that aminoguanidine induces VEGF mRNA expression in stored hair follicle micrografts and outer root sheath cells, suggesting potential for enhancing growth factor production during storage.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This article discusses developing a standardized operating procedure for PRP administration to align with infection prevention regulatory standards and reports no new clinical results.